Zevra Therapeutics, Inc. (ZVRA)

NMS – Real vaqt narxi. Valyuta: USD

11.05

+0.25 (2.31%)

Yopilishda: May 12, 2026, 4:00 PM EDT

07.05.2026

Zevra Therapeutics, Inc. (ZVRA) Q1 2026 Earnings Call Transcript

06.05.2026

Zevra Therapeutics (ZVRA) Q1 Earnings and Revenues Surpass Estimates

Zevra Therapeutics (ZVRA) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to a loss of $0.06 per share a year ago.

06.05.2026

Zevra Reports First Quarter 2026 Financial Results and Corporate Update

Q1 2026 net revenue of $36.2 million , a 78% increase over Q1 2025 Completed $50.0 million sale of SDX portfolio to Commave Therapeutics Operational execution fueled strong cash position of $236.8 million Company to host conference call and webcast TODAY, May 6, 2026 , at 4:30 p.m. ET BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today reported its financial results for the first quarter ended March 31, 2026.

20.03.2026

Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, March 20, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company has granted as of March 18, 2026 an equity inducement award to Justin Renz, the Company's new Chief Financial Officer pursuant to the Company's 2023 Employment Inducement Award Plan (as amended and/or restated, the “Inducement Award Plan”). The equity award was approved by the Compensation Committee of the Board of Directors in accordance with Nasdaq Rule 5635(c)(4) and made as a material inducement to Mr. Renz upon acceptance of employment with Zevra.

16.03.2026

Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million

BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced an agreement under which Commave Therapeutics SA (Commave) will purchase Zevra's serdexmethylphenidate (SDX) portfolio, including AZSTARYS® and KP1077, for $50 million. "We are pleased to have reached a mutually beneficial agreement with Commave regarding the sale of our entire SDX portfolio," said Neil F.

10.03.2026

Why Zevra Therapeutics Stock Zoomed 21% Higher Today

It also posted 44% net revenue growth for the period. Both headline figures crushed the consensus analyst estimates.

10.03.2026

Zevra Therapeutics: Miplyffa Uptake Validates Rare Disease Commercial Model

Zevra Therapeutics delivered robust FY25 results, with 350% revenue growth to $106.5M and a GAAP EPS of $1.40, driven by Miplyffa's commercial launch. Miplyffa's rapid adoption in the ultra-rare NPC market, supported by expanded payer coverage and diagnostic initiatives, underpins ZVRA's strong commercial momentum. ZVRA trades at discounted valuation multiples (16.9x forward P/E, 10.7x EV/EBIT), reflecting market caution over one-time income and earnings sustainability.

Videolar

No Data

There is no data to display

Press-relizlar

06.05.2026

Zevra Reports First Quarter 2026 Financial Results and Corporate Update

20.03.2026

Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)

16.03.2026

Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million

02.03.2026

Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call

CELEBRATION, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it will report corporate and financial results for the fourth quarter and full year 2025 on Monday, March 9, 2026, via a news release after the market close, and will host a conference call/audio webcast at 4:30 p.m. ET that day.

Zevra Therapeutics, Inc. (ZVRA)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Zevra Therapeutics, Inc. (ZVRA)

Zevra Therapeutics, Inc. (ZVRA) Q1 2026 Earnings Call Transcript

Zevra Therapeutics (ZVRA) Q1 Earnings and Revenues Surpass Estimates

Zevra Reports First Quarter 2026 Financial Results and Corporate Update

Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)

Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million

Why Zevra Therapeutics Stock Zoomed 21% Higher Today

Zevra Therapeutics: Miplyffa Uptake Validates Rare Disease Commercial Model

Videolar

No Data

Press-relizlar

Zevra Reports First Quarter 2026 Financial Results and Corporate Update

Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)

Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million

Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call

Zevra Therapeutics, Inc. (ZVRA) Q1 2026 Earnings Call Transcript

Zevra Therapeutics (ZVRA) Q1 Earnings and Revenues Surpass Estimates

Zevra Reports First Quarter 2026 Financial Results and Corporate Update

Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)

Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million

Why Zevra Therapeutics Stock Zoomed 21% Higher Today

Zevra Therapeutics: Miplyffa Uptake Validates Rare Disease Commercial Model

Videolar

No Data

Press-relizlar

Zevra Reports First Quarter 2026 Financial Results and Corporate Update

Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)

Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million

Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call

Search stocks

Zevra Therapeutics, Inc. (ZVRA)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Zevra Therapeutics, Inc. (ZVRA)

Zevra Therapeutics, Inc. (ZVRA) Q1 2026 Earnings Call Transcript

Zevra Therapeutics (ZVRA) Q1 Earnings and Revenues Surpass Estimates

Zevra Reports First Quarter 2026 Financial Results and Corporate Update

Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)

Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million

Why Zevra Therapeutics Stock Zoomed 21% Higher Today

Zevra Therapeutics: Miplyffa Uptake Validates Rare Disease Commercial Model

Videolar

No Data

Press-relizlar

Zevra Reports First Quarter 2026 Financial Results and Corporate Update

Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)

Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million

Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call

Zevra Therapeutics, Inc. (ZVRA) Q1 2026 Earnings Call Transcript

Zevra Therapeutics (ZVRA) Q1 Earnings and Revenues Surpass Estimates

Zevra Reports First Quarter 2026 Financial Results and Corporate Update

Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)

Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million

Why Zevra Therapeutics Stock Zoomed 21% Higher Today

Zevra Therapeutics: Miplyffa Uptake Validates Rare Disease Commercial Model

Videolar

No Data

Press-relizlar

Zevra Reports First Quarter 2026 Financial Results and Corporate Update

Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)

Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million

Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call